EP0914615A1 - Procede pour etablir directement la preuve diagnostique de mutations ponctuelles pathogenes d'ordre genetique - Google Patents

Procede pour etablir directement la preuve diagnostique de mutations ponctuelles pathogenes d'ordre genetique

Info

Publication number
EP0914615A1
EP0914615A1 EP97929238A EP97929238A EP0914615A1 EP 0914615 A1 EP0914615 A1 EP 0914615A1 EP 97929238 A EP97929238 A EP 97929238A EP 97929238 A EP97929238 A EP 97929238A EP 0914615 A1 EP0914615 A1 EP 0914615A1
Authority
EP
European Patent Office
Prior art keywords
protein
analysis
examined
medical
pathogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97929238A
Other languages
German (de)
English (en)
Inventor
Wolf-Georg Forssmann
Manfred Raida
Bernhard Brenner
Volker Nier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemopep Pharma GmbH
Original Assignee
Haemopep Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemopep Pharma GmbH filed Critical Haemopep Pharma GmbH
Publication of EP0914615A1 publication Critical patent/EP0914615A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive

Definitions

  • the present invention relates to a method according to the preamble of claim 1.
  • Mutations at the gene level often result in the incorporation of amino acids, which are not intended per se, into proteins which are coded on the corresponding mutated gene segment. This can lead to pathological symptoms, see e.g. sickle cell anemia. Investigations of whether mutations that are responsible for pathological conditions are usually carried out at the DNA level. Such examinations are complex and their evaluation regularly takes a very long time.
  • One problem on which the invention is based is therefore to provide a method with which it is possible to determine the presence of mutations quickly and reliably.
  • the method according to the invention is used to detect mutations in organisms by comparing a mutation-caused deviation in the amino acid composition of a protein expressed in the region of the mutation as the protein to be investigated, in comparison with a corresponding protein which is of a wild type which has the mutation does not have, is expressed.
  • the method according to the invention is characterized in that
  • a sample is taken from the organism at a point at which the protein to be examined is expressed, can be detected and / or plays a physiological role,
  • the protein is either enriched or purified using protein analytical methods, followed by molecular weight determination, or
  • a molecular weight determination of the protein to be examined is carried out without pretreatment from the sample.
  • the invention advantageously relates to a rapid method for medical-diagnostic qualitative! and quantitative analysis at the protein level for the exchange of individual amino acids with pathogenic or non-pathogenic effects on the organism.
  • the medical-diagnostic analysis is preferably carried out by combining enzymatic or chemical cleavage of the isolated peptide, chromatographic separation of the fragments and analysis via mass spectrometry, both direct LC / MS and indirect MALDI-MS and analysis z. B. via capillary electrophoresis.
  • samples from an organism can be regarded as a basis for the method according to the invention.
  • locations at which the samples are taken those locations are selected at which the protein to be examined is expressed, is detectable or plays a physiological role, for example in muscle fiber bundles or tissue pieces from organs, especially hearts.
  • the samples are advantageously processed in such a way that the exchange of a single amino acid can be clearly identified by mass spectrometric, chromatographic and / or electrophoretic methods and the expression and incorporation ratio between wild form and mutant can be determined quantitatively. This means that direct protein analysis also makes it possible to diagnose the causes of a genetic disease at an early stage and to identify previously unknown mutations by comparing samples from healthy people with samples from sick people.
  • MALDI-MS laser-induced desorption and ionization flight time mass spectrometry
  • the method is distinguished from the previously used analyzes of the DNA coding for the proteins in that the detection of the mutation and the determination of the expression and incorporation ratio take place in a significantly shorter time. An analysis must be carried out within a week, in contrast to the usual analysis times for DNA analysis from several weeks to half a year. It is advantageous that a specific cleavage of the; Protein obtained from biopsy samples for diagnostic purposes with selective enzymes, endoproteinases or by chemical reagents, and the fragments obtained by this cleavage are separated by chromatographic methods and directly (LC / MS) or indirectly (MALDI-MS) on their molecular weights are characterized. The distribution of the separation and the molecular weight, determined by mass spectrometry, is clear evidence for each fragment of the protein.
  • the amino acid exchanges can be determined directly with the described method, without prior cleavage into fragments. Due to the accuracy of the measurement, it is possible to precisely determine deviations in the molecular weight of ⁇ 5 daltons and thus to detect wild forms in addition to mutants. The exact localization of the amino acid exchange can take place with the cleavage described above.
  • this method is also used in clinical diagnostic detection the cause of diseases and, by optimizing the separation and detection conditions, can also be adapted to systematically screen patient samples for specific, defined mutations.
  • the method described can also be largely automated using suitable devices.
  • the analysis duration for the described procedure is in the range of a few days, while the DNA analysis takes several weeks to months. At the same time, all proteins involved in a physiologically functional structure can be analyzed with it.
  • this method In contrast to the usual methods for the detection of point mutations by analysis of the genomic DNA or the cDNA, this method also allows the expression and the incorporation of the mutant into the physiologically functional structure, especially if due to the double set of chromosomes present in the cell nucleus, both forms of the protein in question are expressed and in the functional form it is not known in what ratio the two forms are present.
  • the invention further enables the identity of the wild type and the mutant to be proven by chemical sequence analysis or by amino acid analysis.
  • a preferred embodiment of the method according to the invention consists in the cleavage of the protein to be examined with suitable enzymes or chemical reagents, the combination of chromatographic methods, in particular high-pressure liquid chromatography with capillary columns (MB-HPLC) and mass spectrometry.
  • the invention is explained in more detail using the example of the heavy chain of the ⁇ -isoform of myosin.
  • Point mutations in the heavy chain of the ß-isoform of myosin e.g. the Replacing the amino acid valine at position 606 with the amino acid methionine can lead to hypertrophic cardiomyopathy, a genetic thickening of certain heart walls, which can lead to sudden death.
  • the detection of the mutation is possible by combining an enzymatic cleavage with the LC / MS.
  • FIGS. 1 a and 1 b show the analysis of the peptide fragment: the human cardiac heavy chain of ⁇ -myosin ( ⁇ -MHC) with the aid of the coupling of high performance liquid chromatography (HPLC) with mass spectrometry (MS).
  • ⁇ -MHC human cardiac heavy chain of ⁇ -myosin
  • HPLC high performance liquid chromatography
  • MS mass spectrometry
  • FIG. 1 a shows two marked areas in which, in addition to the original fragment, the wild-type fragment with a molecular weight of 1475.5, in addition to the fragment with the amino acid exchange and a in a person in whom the exchange had been proven at the gene level Molecular weight of 1507.5 could be demonstrated.
  • Figure 1b shows the analysis of a ⁇ -MHC sample of a person without a point mutation in the gene. Only the wild-type fragment can be detected here; in the area in which the mutated fragment eluted in FIG. 1 a, this peptide is completely absent. The mutated ⁇ -MHC can thus be detected in a person's muscle fibers.
  • the peptides detected in the fractions were confirmed in their sequence via the collision-induced fragmentation with the aid of the coupling of two mass spectrometers (CID-MS / MS).
  • the distances between the fragment ions denoted by b and y correspond highly specifically to the amino acids of the peptides.
  • the sequence of the peptide can be determined in whole or in part from these distances. Problems only arise with the amino acids Leu and Ile, which have no molecular weight differences and Lys and Gin, which differ by only 0.04 mass units. Since the enzymatic cleavage was carried out with an enzyme which cleaves specifically behind Lys, it can be assumed for the sequence determination that amino acids are a Lys at the end of the peptide.
  • the CID-MS / MS spectra are shown in FIGS. 3a and 3b.
  • the distance between b5 and b6 clearly shows the shift due to the amino acid exchange, while all other distances between the fragment ions remain unchanged.
  • the evaluation resulted in sequences DPLNETWGLYQK for the wild type and DPLNETVMGLYQK for the mutant.
  • Database comparisons showed no homology of the CID-MS / MS spectra to other proteins, except for very homologous ß-MHC of other species. The presence of the mutation in the muscle fibers could thus be clearly demonstrated at the molecular level.
  • the buffer used has a pH of 2.5 (100 mM phosphate buffer) in order to exclude electroendo-osmotic flows of the buffer itself and to charge all peptides positively.
  • the. Peptides of the identified fractions separated.
  • a commercially available peptide Iow-pH mobility marker from Applied Biosystems
  • the peptides themselves were identified in further separations by co-injection with the synthetic peptide of the same sequence.
  • the method according to the invention can generally be applied to all mutants of the ⁇ -MHC. So far, the Identification of several fragments which are potential carriers of mutations, these fragments are underlined in FIG. 5, the amino acids written under the continuous sequence are the exchanges known to date. Furthermore, the method according to the invention can be applied to all mutations with a pathogenic effect. This method can be used diagnostically for the early detection of the development of inheritable diseases. In addition to genetic analysis, direct analysis of the risk of a serious disease or of a course of the disease can be made for each patient by analyzing the functioning proteins from the organism become.
  • the basis of the selective cleavage is the isolation of the .beta.-MHC from muscle fibers of the soleus muscle, which are obtained in the context of biopsies, by dissolving in a buffer with a high salt concentration and precipitation of the .beta.-MHC by lowering the salt concentration.
  • the present ⁇ -MHC can be washed with water to remove interfering soluble components.
  • the sample is passed through a 0.2 ⁇ m cellulose acetate filter at a maximum of 10,000 IQ -
  • peptides are eluted by a linear increase of 0.5% / min in the acetonitrile concentration in the buffer, starting from 10% acetonitrile in 0.06% TFA in water to 80% acetonitrile in 0.05% TFA in water.
  • the eluting peptides are passed through a fused silica capillary via a UV detector directly into the electrospray ionization device of the quadrupole mass spectrometer (SCIEX API III, Perkin-Elmer, Langen).
  • SCIEX API III electrospray ionization device of the quadrupole mass spectrometer
  • the m / z (mass to charge) values are determined every 4.2 seconds over a range from 400 to 2400 amu (atomic mass units).
  • the fragment of the wild type and the mutants can be detected from the recorded total ion chromatogram and the respective mass spectra by computer-aided evaluation.
  • Fig. 1 Upper area: total ion chromatogram of the separation of the fragments of the mutated ⁇ -MHC obtained by endoproteinase Lys-C.
  • Middle area detection of the non-mutated fragment in the hatched area (1) of the upper image.
  • the non-mutated fragment has a molecular weight of 1475.5. amu.
  • the ⁇ -MHC was cleaved by incubation with endoproteinase Lys-C and a subsequent separation using a reverse-phase C18 column under the conditions specified above.
  • an automatic fraction collector collects fractions every 2 minutes and 0.5 ⁇ l of each of these fractions with 1 ⁇ l of a suitable matrix substance, usually alpha-hydroxycinnamic acid or sinapic acid, dissolved in 60% acetonitrile and 0.2% TFA , mixed on a carrier for the MALDI-MS.
  • the molecular weights are then determined in a MALDI-MS (Vestec, Houston) using an external standard, i.e. two known synthetic peptides, for calibration of the measurement.
  • the mutated fragments can thus be clearly detected with the aid of MALDI-MS.
  • the fractions from example 2 were subjected to capillary electrophoresis (Beckmann P / ACE 2000, Beckman Kunststoff) using fused silica capillaries with an inner diameter of 75 ⁇ m in a buffer with 100 mM sodium phosphate, pH 8.0, at a Voltage from 15 to 17 kV separated.
  • the peptides are detected using a UV detector at 200 nm.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé rapide d'analyse qualitative et quantitative, à des fins diagnostiques et médicales, sur le plan des protéines, dans le cadre de l'échange de différents aminoacides à effets pathogènes ou non-pathogènes sur l'organisme. L'analyse médicale-diagnostique s'effectue en combinant une scission enzymatique ou chimique du peptide isolé avec une séparation chromatographique des fragments et une analyse par spectrométrie de masse directe LC/MS et spectrométrie de masse indirecte MALDI-MS et une analyse par électrophorèse capillaire. En comparant les échantillons de protéines provenant de sujets sains avec des échantillons provenant de sujets malades, on peut déterminer, avec le procédé selon l'invention de nouvelles mutations, inconnues jusqu'à présent, et quantifier l'expression et l'incorporation d'un type sauvage en mutant.
EP97929238A 1996-06-21 1997-06-20 Procede pour etablir directement la preuve diagnostique de mutations ponctuelles pathogenes d'ordre genetique Withdrawn EP0914615A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19624802 1996-06-21
DE19624802A DE19624802A1 (de) 1996-06-21 1996-06-21 Verfahren zum direkten diagnostischen Nachweis von pathogenen, genetisch bedingten Punktmutationen in Proteinen bei Herzerkrankungen durch chemische und physikalische Methoden, besonders der direkten und indirekten Kopplung der Hochdruck-Flüssigkeitschromatographie und der Massenspektrometrie
PCT/EP1997/003241 WO1997049993A1 (fr) 1996-06-21 1997-06-20 Procede pour etablir directement la preuve diagnostique de mutations ponctuelles pathogenes d'ordre genetique

Publications (1)

Publication Number Publication Date
EP0914615A1 true EP0914615A1 (fr) 1999-05-12

Family

ID=7797590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97929238A Withdrawn EP0914615A1 (fr) 1996-06-21 1997-06-20 Procede pour etablir directement la preuve diagnostique de mutations ponctuelles pathogenes d'ordre genetique

Country Status (5)

Country Link
US (1) US6326163B1 (fr)
EP (1) EP0914615A1 (fr)
JP (1) JP2000513439A (fr)
DE (1) DE19624802A1 (fr)
WO (1) WO1997049993A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108802227A (zh) * 2018-06-19 2018-11-13 大连工业大学 生物活性多肽序列的联合鉴定方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
GB9807915D0 (en) * 1998-04-14 1998-06-10 Shimadzu Res Lab Europe Ltd Apparatus for production and extraction of charged particles
EP1285092A4 (fr) * 2000-04-14 2003-07-16 Metabolon Inc Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2002327704A1 (en) * 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
WO2003067244A2 (fr) * 2002-02-08 2003-08-14 Ionalytics Corporation Faims a detection non destructive d'ions transmis selectivement
AU2003301882A1 (en) * 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
US20060281101A1 (en) * 2005-02-17 2006-12-14 The Regents Of The University Of California Biobriefcase
WO2008033575A2 (fr) * 2006-09-15 2008-03-20 Metabolon, Inc. Procédés d'identification de cheminements biochimiques
US9695479B2 (en) * 2010-11-08 2017-07-04 The Johns Hopkins University Medulloblastoma genes as targets for diagnosis and therapeutics
EP3805756A1 (fr) 2014-04-08 2021-04-14 Metabolon, Inc. Profilage biochimique de petites molécules de sujets individuels pour un diagnostic de maladie et une évaluation de santé

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208458A (en) * 1991-11-05 1993-05-04 Georgia Tech Research Corporation Interface device to couple gel electrophoresis with mass spectrometry using sample disruption
US5912121A (en) * 1992-12-11 1999-06-15 Bringham And Women's Hospital Methods for detecting mutations associated with hypertrophic cardiomyopathy
US5429923A (en) 1992-12-11 1995-07-04 President And Fellows Of Harvard College Method for detecting hypertrophic cardiomyophathy associated mutations
US6017693A (en) * 1994-03-14 2000-01-25 University Of Washington Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9749993A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108802227A (zh) * 2018-06-19 2018-11-13 大连工业大学 生物活性多肽序列的联合鉴定方法

Also Published As

Publication number Publication date
JP2000513439A (ja) 2000-10-10
WO1997049993A1 (fr) 1997-12-31
DE19624802A1 (de) 1998-01-02
US6326163B1 (en) 2001-12-04

Similar Documents

Publication Publication Date Title
EP0922226B2 (fr) Procede de determination de l'etat d'un organisme par mesure des peptides
EP0021152B1 (fr) Procédé pour la détermination immunologique d'une matière de membrane basale, fragments de membranes basales spécifiques pour ce procédé et procédé pour leur préparation, resp. leur obtention
EP0914615A1 (fr) Procede pour etablir directement la preuve diagnostique de mutations ponctuelles pathogenes d'ordre genetique
WO2001084140A2 (fr) Procede et dispositif de determination qualitative et/ou quantitative d'un modele proteique et/ou peptidique d'un echantillon de liquide, preleve d'un corps humain ou animal
EP1451590A2 (fr) Peptides et procede permettant de detecter la maladie d'alzheimer et de differencier cette maladie par rapport aux autres maladies demencielles
DE60114018T2 (de) Von zellen präsentierte peptide
DE60109490T2 (de) Umgekehrtes labelierungsverfahren zur schnellen identifikation von marker/ziel-proteinen
EP1381628B1 (fr) Peptides specifiques d'inflammations et leurs utilisations
DE10158860A1 (de) Massenspektrometrische Proteingemischanalyse
DE10130985A1 (de) Verwendung löslicher Cytokeratin-1-Fragmente in Diagnostik und Therapie
WO2009115570A2 (fr) Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux
EP1972940A1 (fr) Procédé et marqueur destinés à diagnostiquer des maladies des reins
DE602004008439T2 (de) Diagnose von autismus
DE60225140T2 (de) Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
DE10131922A1 (de) Verwendung des Calcineurin B Homologen Proteins (CHP) für die Diagnose und Therapie von Entzündungserkrankungen und Sepsis
WO2003098182A2 (fr) Procede de quantification de molecules
WO2007000466A1 (fr) Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce
DE102006041644B4 (de) Verfahren zur Detektion von Modifikationen in einem Protein oder Peptid
DE19632521A1 (de) Verfahren zur Gewinnung von Peptiden aus Köperflüssigkeiten und Geweben sowie Zellüberständen und zur Identifikation von krankheitsrelevanten Peptidmarkern
DE102008043241B3 (de) Verfahren zur massenspektrometrischen relativen Quantifizierung von Peptiden markiert mit 36S mittels metabolischer Markierung
DE102020103267A1 (de) Verfahren und Vorrichtung zum Nachweis von Schlachtnebenprodukten und/oder Separatorenfleisch
WO2004097420A1 (fr) Procede pour depister une maladie dementielle neurologique associee a une degradation de la memoire a court ou a long terme, peptides de prosaas associes et reactifs de depistage
WO2012123527A1 (fr) Procédé et marqueurs de diagnostic de formes infracliniques et cliniques du rejet tubulo-interstitiel à médiation lymphocytaire t après une transplantation rénale
DE10155692A1 (de) Verfahren zum Nachweis von endogenen und exogenen Stoffen im Organismus
DE10149568A1 (de) Verfahren zur Sequenzanalyse von Polypeptiden

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE FR GB IT LI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000103